Lipella pharmaceuticals re-signs manufacturing collaboration agreement with cook myosite to support lp-310 clinical development

Supports late-stage development and scalable manufacturing for lp-310, a non-steroidal oral rinse therapy for oral lichen planus, a condition with no approved treatments pittsburgh, june 4, 2025 – prism mediawire – lipella pharmaceuticals inc.
LIPO Ratings Summary
LIPO Quant Ranking